PointofLaw.com
 Subscribe Subscribe   Find us on Twitter Follow POL on Twitter  
   
 
   

 

 

What next for Merck?



Richmond attorney/lawprof Cullen Seltzer surveys the options for the drug firm and its opponents after the Vioxx verdict (via Prawfsblawg). More: plaintiff's lawyer Dwight Meredith argues that the "Texas case had a number of disadvantages for Merck that may not be present in subsequent cases" and concludes, "I think that it is quite possible that the Vioxx litigation is now at its high water mark for plaintiffs. I suspect that things will look better for Merck once the Daubert standard is applied, a few defense verdicts are reached, and the Texas verdict gets reduced (as it will) or reversed."

 

 


Rafael Mangual
Project Manager,
Legal Policy
rmangual@manhattan-institute.org

Katherine Lazarski
Manhattan Institute
klazarski@manhattan-institute.org

 

Published by the Manhattan Institute

The Manhattan Insitute's Center for Legal Policy.